Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
In brief
CTNM shares slid sharply after its Phase 2 depression trial failed to meet the primary endpoint, casting doubt on the drug’s future and impacting both companies’ outlooks.
ClearTape summarizes context in-app. For the full publisher article, use Read original source above.